GastroenterologyNews.net

Gastroenterology Xagena

RPC1063 is an orally available, potent, selective sphingosine-1-phosphate 1 receptor ( S1P1R ) agonist, which has been shown to decrease inflammation in animal models of colitis. Stimulation of S1P1 ...


The objective of a study was to evaluate the impact of a diet and physical activity intervention ( BeWEL ) on weight change in people with a body mass index greater than 25 weight (kg) / height (m)2 a ...


Compared with open resection, laparoscopic resection of rectal cancers is associated with improved short-term outcomes, but high-level evidence showing similar long-term outcomes is scarce. The tria ...


Diverticulitis is a common disease. Recent changes in understanding its natural history have substantially modified treatment paradigms. It has been reviewed the etiology and natural history of div ...


Postoperative pancreatic fistula is a major contributor to complications and death associated with pancreatic resection. Pasireotide ( Signifor ), a somatostatin analogue that has a longer half-life t ...


Tofacitinib ( Xeljanz ), an orally administered Janus kinase inhibitor, blocks signaling through gamma-chain-containing cytokines ( interleukins 2, 4, 7, 9, 15, and 21 ). Researchers have performed ...


Eli Lilly has announced that the FDA ( Food and Drug Administration ) has approved Cyramza ( Ramucirumab ) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastro ...


The alpha4beta7 integrin monoclonal antibody Vedolizumab ( Entyvio ) is hypothesised to be gut selective. Effects of Vedolizumab on immune responses to parenterally or enterally administered antigens ...


The objective of a study was to compare high-definition white-light endoscopy ( HDWLE ) alone with random biopsy ( RB ) and HDWLE plus eCLE ( endoscope-based confocal laser endomicroscopy system ) and ...


Optimizing anti-tumor necrosis factor therapy is often required in patients with Crohn's disease. In case of partial response or loss of response to Adalimumab ( Humira ) 40 mg every other week, the i ...


Vedolizumab ( Entyvio ) is a humanized monoclonal antibody that inhibits adhesion and migration of leukocytes into the gastrointestinal tract by preventing the alpha4beta7 integrin subunit from bindin ...


A new generation of oral anticoagulants ( nOAC ), which includes thrombin and factor Xa inhibitors, has been shown to be effective, but little is known about whether these drugs increase patients' ris ...


In the past decades, prophylactic colectomy to prevent development of colorectal cancer substantially has improved prognosis in patients with familial adenomatous polyposis ( FAP ). The mortality patt ...


A phase III clinical trial of the drug Abraxane ( nanoparticle albumin-bound Paclitaxel; Nab-Paclitaxel ) in combination with current standard of care Gemcitabine ( Gemzar ) in patients with advanced ...


Travellers' diarrhoea causes substantial acute and long-term morbidity. Chemoprophylaxis with fluoroquinolones or Rifaximin ( Normix, Xifaxan ) is effective in prevention of diarrhoea in individuals t ...


A systematic review and meta-analysis of data from randomized controlled trials ( RCTs ) to evaluate the efficacy and safety of Certolizumab pegol ( Cimzia ) was performed. A total of five RCTs, in ...


Whether sequential treatment can replace triple therapy as the standard treatment for Helicobacter pylori infection is unknown.The efficacy of sequential treatment for 10 days and 14 days with triple ...


The efficacy of Vedolizumab ( Entyvio ), an alpha4beta7 integrin antibody, in Crohn's disease is unknown.In an integrated study with separate induction and maintenance trials, researchers have assesse ...


The hemoglobin threshold for transfusion of red cells in patients with acute gastrointestinal bleeding is controversial. Researchers have compared the efficacy and safety of a restrictive transfusion ...


Results of the phase II, randomized, double-blind, placebo-controlled RECAP trial of Ruxolitinib ( Jakafi ), its oral JAK1 and JAK2 inhibitor, in combination with Capecitabine ( Xeloda ) in patients w ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati